Oct 08th 2012 - Edison Investment Research today published a report on Neovacs entitled "Interferon With Lupus". In summary, the report says:
Roche’s recent decision to advancerontalizumab, theiranti-interferon-alpha (IFNα) antibody, into Phase III trials for lupussuggests that clinical proof-of-concept has been achieved in Phase II trials. This lends validation to Neovacs’sIFNα-Kinoid, which has completed a Phase I/II trial for lupus with encouraging efficacy data. Neovacs is currently planning a Phase IIb trial in lupus. Separately, it is planning a Phase IIb for the TNFα-Kinoidin rheumatoid arthritis (RA) andis expecting final results of a Phase IIa study in Crohn’s Disease (CD). Additional positive Phase II trial data could attract a licensing partner.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
